C4 Therapeutics, Inc. (CCCC) Earnings Call Transcripts
C4 Therapeutics, Inc.'s Latest Earnings Call - June 18, 2026
In the Q2 2026 earnings call, C4 Therapeutics (CCCC:US) highlighted significant advancements in their lead asset, Cemsidomide, a next-generation IKZF1/3 degrader for multiple myeloma. The company reported a response rate of 36% across all dose levels in a heavily pretreated patient population, with a peak response rate of 53% at the highest dose. Management maintained their guidance for the Phase III MOMENTUM trial, expecting initial data in late 2027, while emphasizing the drug's potential to be a best-in-class treatment. Revenue and earnings details were not disclosed in this call, but the focus on Cemsidomide's clinical profile and future trials could drive investor interest and stock movement.
Reported metrics
| Metric | Value |
|---|---|
| Overall Response Rate | 36% (positive) |
| Response Rate at RP2D | 53% (positive) |
| Neutropenia Rate (Grade 3/4) | 22% (positive) |
| Enrollment Completion for MOMENTUM Trial | End of Q1 2027 (neutral) |
| Cemsidomide Dosing Schedule | 14-day on, 14-day off (positive) |
| Median Lines of Prior Therapy | 7 (neutral) |
Guidance from management
Management reiterated their commitment to advancing Cemsidomide through clinical trials, with a focus on combination therapies and addressing unmet needs in multiple myeloma treatment. They expect to provide further updates on the Phase Ib trial with elranetinab in mid-2027.
What management said
Yes. And I'll just add, I think the two comparative sort of points we can point to for what that kind of Palm KD arm is going to look like? Or is this IT called the SELECT study of 52 patients where there was an 11.1-month PFS. And then if you look at the comparator arm to the Majestic 9 study, which is a very similar patient population. We saw that have about an 8-ish month PFS. So that's another way to handicap suc...
And I'll add one other comment is what's really also important is the selectivity of Cemsidomide. When you think about the first gen, right? No one do the mechanism so they can't be selective. They -- they rate a number of other NeOsubstrates like GSPT1 and CK1 alpha. And when you think about combining them with a bite, you really want to do the safest, most tolerable one because there can be overlapping toxicities a...
What analysts pressed on
Analysts raised questions regarding the comparative efficacy of Cemsidomide versus existing therapies like pomalidomide, particularly in earlier treatment lines. There were also inquiries about the potential for overlapping toxicities when combined with bispecific antibodies, highlighting concerns about patient safety and treatment tolerability.
Main topics on the call
- Cemsidomide's Clinical Profile — Cemsidomide demonstrated a 36% overall response rate in a Phase I trial, with a peak of 53% at the highest dose level of 100 micrograms. Management stated, "Cemsidomide is built on novel chemistry with a well-understood ...
- Phase III MOMENTUM Trial Update — The Phase III MOMENTUM trial is currently enrolling patients and aims for accelerated approval based on the unmet need in late-line multiple myeloma therapy. Initial data is expected in the second half of 2027, with mana...
- Market Positioning and Strategy — C4 Therapeutics is focusing on establishing Cemsidomide as a foundational backbone therapy across multiple treatment lines, with plans for combination studies with BCMA-targeted therapies. Management noted, "Our goal is ...
- Safety Profile of Cemsidomide — Cemsidomide was reported to have a favorable safety profile, with low rates of neutropenic complications and manageable side effects. Management highlighted that "there were no discontinuations related to Cemsidomide and...
Read the full C4 Therapeutics, Inc. transcript (June 18, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc. (CCCC) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 18 calls on record spanning January 14, 2021 to June 18, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 18 C4 Therapeutics, Inc. earnings call transcripts on record, spanning January 14, 2021 to June 18, 2026. Based on this history, C4 Therapeutics, Inc. reports semi-annually. The most recent call on file is dated June 18, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- CCCC
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 18
- First call
- January 14, 2021
- Most recent
- June 18, 2026
- Reporting cadence
- semi-annually